https://www.selleckchem.com/pr....oducts/LY315920(Vare
27 and 0.23. The ICER of BCP versus CP was $ 465 150 QALY. The results of the Monte Carlo simulation showed that CP was cost-effective in 100% of the iterations compared with BCP. The addition of bevacizumab to the scheme carboplatin+ paclitaxel compared to carboplatin+ paclitaxel for NSCLC is not cost-effective from the point of view of the Colombian health system. The addition of bevacizumab to the scheme carboplatin + paclitaxel compared to carboplatin + paclitaxel for NSCLC is not cost-effective from the point of view